WO2022144836 - MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKP46 AND CD123
National phase entry:
Publication Number
WO/2022/144836
Publication Date
07.07.2022
International Application No.
PCT/IB2021/062494
International Filing Date
30.12.2021
Title **
[English]
MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKP46 AND CD123
[French]
AGENTS D'ACTIVATION DE CELLULES TUEUSES NATURELLES (NK) MULTIFONCTIONNELS SE LIANT À NKP46 ET CD123
Applicants **
SANOFI
46 avenue de la Grande Armée
75017 Paris, FR
INNATE PHARMA
117 avenue de Luminy
F13009 Marseille, FR
Inventors
GAUTHIER, Laurent
c/o Innate Pharma
117 avenue de Luminy
F13009 Marseille, FR
THIELENS, Ariane
c/o Innate Pharma
117 avenue de Luminy
F13009 Marseille, FR
ROSSI, Benjamin
c/o Innate Pharma
117 avenue de Luminy
F13009 Marseille, FR
AMARA, Céline
c/o Sanofi
54 rue La Boétie
75008 Paris, FR
NICOLAZZI, Céline
c/o Sanofi
54 rue La Boétie
75008 Paris, FR
CHIRON, Marielle
c/o Sanofi
54 rue La Boétie
75008 Paris, FR
DUFFIEUX, Francis
c/o Sanofi
54 rue La Boétie
75008 Paris, FR
VIRONE-ODDOS, Angela
c/o Sanofi
54 rue La Boétie
75008 Paris, FR
BENINGA, Jochen
c/o Sanofi-Aventis Deutschland GmbH,
Patent Department
65926 Frankfurt am Main, DE
Priority Data
20306717.8
31.12.2020
EP
63/256,950
18.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2591 | |
| EPO | Filing, Examination | 12170 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 606 | |
| USA | Filing, Examination | 10410 |
Total: 26365 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-γ receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).[French]
La présente divulgation concerne des protéines de liaison multifonctionnelles comprenant un premier et un second domaines de liaison à l'antigène (ABD) et tout ou partie d'une région Fc d'immunoglobuline ou d'un variant de celle-ci, le premier ABD se liant de manière spécifique au CD123 humain et le second ABD se liant de manière spécifique à NKp46 humain et tout ou partie de la région Fc d'Immunoglobuline ou d'un variant de celle-ci à un récepteur Fc-γ humain. La divulgation concerne également des procédés de fabrication desdites protéines de liaison, des compositions de celles-ci, et leurs utilisations, comprenant le traitement ou la prévention de troubles prolifératifs, y compris la leucémie myéloïde aiguë (AML) et des syndromes myélodysplasiques (MDS).